New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2012
09:59 EDTWLP, SQNMWellpoint deems Sequenom pre-natal tests medically necessary for some patients
In a medical policy update with an effective date of Dec. 19, 2012, health insurer Wellpoint (WLP) stated that it views cell-free fetal DNA-based prenatal screening for fetal aneuploidies, including but not limited to Trisomy 13, Trisomy 18 and Trisomy 21, medically necessary for its members when certain criteria are met. Wellpoint stated there are currently several commercially available laboratory developed tests which analyze circulating cell-free DNA to identify increased representation of various chromosomes, including but not necessarily limited to the Sequenom's (SQNM) MaterniT21 Test and its MaterniT21 Plus Test, among others from Verinata Health and Aria Diagnostics. In early morning trading, shares of Sequenom rose 32c, or 6.84%, to $4.96, with the strength being attributed by some to Wellpoint's approval. Reference Link
News For SQNM;WLP From The Last 14 Days
Check below for free stories on SQNM;WLP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
11:31 EDTWLPAetna rises after topping expectations, raising guidance
Shares of healthcare insurer Aetna (AET) are advancing after its first quarter results topped analysts' consensus estimates and it raised its fiscal 2014 outlook. WHAT'S NEW: This morning, Aetna reported Q1 adjusted earnings per share of $1.98 and revenue of $13.99B, topping expectations of $1.56 and $13.72B, respectively. Medical membership in Q1 increased to over 22.7M, a sequential increase of 529,000 members. Aetna is targeting year-end medical membership of more than 23M, an increase of 800,000-1M members for the year. “Aetna posted higher operating earnings, operating revenues and medical membership in the first quarter, each representing historic highs for our company...This performance is once again a testament to the strength of our diversified portfolio, continued progress in integrating the Coventry acquisition, pricing discipline and solid execution. Our strong membership growth in the quarter came from both our commercial and government businesses, and we project this momentum will continue,” said Mark Bertolini, Aetna chairman, CEO and president. WHAT'S NOTABLE: The company raised its FY14 EPS view to $6.35-$6.55 from at least $6.25, versus consensus of $6.38. It also raised its FY14 revenue outlook to $56B-$57B from at least $54B, compared to consensus of $54.89B. PRICE ACTION: In late morning trading, Aetna rose $3.61, or 5.2%, to $72.52 on heavy trading volume. Including today's advance, the stock up about 27% over the past twelve months. OTHERS TO WATCH: Other companies in the healthcare benefits space include UnitedHealth Group (UNH), Cigna (CI), WellPoint (WLP) and Humana (HUM), all of which are higher on the session.
April 17, 2014
12:53 EDTWLPOn The Fly: Midday Wrap
Subscribe for More Information
10:51 EDTWLPHealth insurers slide after UnitedHealth results, cautious comments
Shares of a number of health insurers are falling after the largest company in the sector, UnitedHealth (UNH), reported slightly higher than expected first quarter profit but lower than expected revenue. WHAT'S NEW: UnitedHealth's first quarter earnings per share came in at $1.10, versus the consensus outlook of $1.09. The insurer reported revenue of $31.71B, compared with the consensus outlook of $31.99B. Taxes levied by the Affordable Care Act and weak funding of Medicare Advantage by the government weighed on UnitedHealth's earnings, the company stated. Also pushing down the company's earnings was "a very expensive," new Hepatitis C therapy, UnitedHealth stated on its earnings conference call. Hepatitis C treatments cost UnitedHealth hundreds of millions of dollars in the first quarter, the company stated, though it also noted that demand for the treatments should drop going forward as initial pent-up demand for them starts to decline. The company indicated that it was looking to be reimbursed by states for the money it is spending on hepatitis vaccines for Medicaid patients. Meanwhile, UnitedHealth reiterated its fiscal 2014 EPS guidance of $5.40-$5.60 and its fiscal 2014 revenue guidance of $128B-$129B. PRICE ACTION: In mid-morning trading, UnitedHealth sank 3.7% to $75.31. Other health insurers also declined, with WellPoint (WLP) dropping 4% to $91.89, Aetna (AET) falling 3.3% to $67.54, Humana (HUM) declining 2.25% to $106.35, and Health Net (HNT) sliding 1% to $31.74.
April 16, 2014
10:08 EDTWLPUnitedHealth retreats after Citi cuts rating on shares
Subscribe for More Information
09:01 EDTWLPWellPoint names Martin Silverstein as Chief Strategy Officer, effective April 28
WellPoint announced Martin Silverstein, M.D., has been named chief strategy officer, effective April 28. In this role, Dr. Silverstein will oversee WellPoint’s enterprise marketing, corporate development and strategy functions, and will be responsible for short and long-term strategic planning to ensure the company is maximizing the value of its assets and capturing growth across its geographies and businesses. Silverstein joins WellPoint from The Boston Consulting Group where he was a Senior Partner and Managing Director.
April 15, 2014
06:32 EDTWLPPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 10, 2014
15:56 EDTWLPWellCare rumored to be takeover target, Betaville blog says
Wellcare (WCG) which has previously been speculated as a takeover target by analysts, is being studied as a target by Wellpoint (WLP), according to the Betaville blog, which cites sources familiar with the matter. Shares of WellCare, which have been lower throughout the session, briefly spiked following the blog post, but have returned to negative territory in late afternoon trading. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use